Drug intelligence / Profile preview

lisinopril + losartan + atorvastatin

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

**lisinopril + losartan + atorvastatin** is a non-standard, hypothetical combination of three medications: lisinopril, losartan, and atorvastatin. - **Lisinopril** is an angiotensin-converting enzyme (ACE) inhibitor used primarily to treat high blood pressure, heart failure, and to improve survival after heart attacks. It works by reducing the production of angiotensin II, leading to vasodilation and reduced blood pressure[1][2]. - **Losartan** is an angiotensin II receptor blocker (ARB) indicated for hypertension, reduction of stroke risk in people with left ventricular hypertrophy, and kidney protection in type 2 diabetes. It blocks angiotensin II receptors, preventing vasoconstriction and lowering blood pressure[1][3]. - **Atorvastatin** is a statin used to lower cholesterol and triglyceride levels, and to reduce cardiovascular risk. It works by inhibiting HMG-CoA reductase, the key enzyme in cholesterol synthesis[6]. This precise triple combination is not known to be marketed as a fixed-dose product, and there are safety concerns about combining both an ACE inhibitor and an ARB due to overlapping mechanisms and risk of adverse effects such as hyperkalemia, hypotension, and renal dysfunction[4]. Fixed-dose combinations more commonly pair an ACE inhibitor or an ARB with a diuretic or a statin, but not both together[5][7].

02

Targets

ACE (Angiotensin Converting Enzyme)AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on lisinopril + losartan + atorvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lisinopril + losartan + atorvastatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call